{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.56","value":"-13.6"},{"groupId":"OG001","spread":"19.79","value":"-11.2"},{"groupId":"OG002","spread":"22.26","value":"-7.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"116"},{"groupId":"OG002","value":"111"}],"units":"Participants"}],"description":"The EuroQol- 5 Dimensions- 5 Levels (EQ-5D-5L) questionnaire consists of the EQ-5D-5L descriptive system and a visual analogue scale (the EuroQol-visual analogue scale \\[EQ-VAS\\]). The respondent's self-rated health is assessed on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state) by the EQ-VAS.","dispersionType":"Standard Deviation","groups":[{"description":"Avelumab 10 milligram (mg)/kilogram (kg) given as a 1-hour intravenous (IV) infusion every 2 weeks (Q2W) in 4-week cycles.","id":"OG000","title":"Avelumab"},{"description":"Avelumab 10 mg/kg given as a 1-hour IV Q2W in 4-week cycles + pegylated liposomal doxorubicin (PLD) 40 mg/square meter given as a 1-hour IV infusion every 4 weeks (Q4W) in 4-week cycles.","id":"OG001","title":"Avelumab + PLD"},{"description":"PLD 40 mg/square meter given as a 1-hour IV infusion Q4W in 4-week cycles.","id":"OG002","title":"Pegylated Liposomal Doxorubicin (PLD)"}],"paramType":"MEAN","populationDescription":"The analysis is based on the FAS. The FAS included all participants who were randomized. 'Number Analyzed' represents number of participants in the FAS with an assessment at the visit or with at least a baseline and post-baseline assessment at visit.","reportingStatus":"POSTED","timeFrame":"Baseline and end of treatment/withdrawal visit","title":"Change From Baseline in EQ-VAS Score at End of Treatment","type":"SECONDARY","unitOfMeasure":"scores on a scale"}